VYNE Therapeutics Inc Dossier
Qualitative Analysis
Business overview
VYNE Therapeutics Inc. (formerly Menlo Therapeutics Inc.) is a clinical-stage biopharmaceutical company historically focused on developing proprietary small-molecule therapies for immuno-inflammatory conditions. Its primary pipeline was centered on its InhiBET™ platform, which includes VYN201 (a topical pan-BD BET inhibitor) and VYN202 (an oral BD2-selective BET inhibitor). However, following clinical-stage setbacks in key trials (such as vitiligo and psoriasis) and a strategic review, the company suspended and began winding down its research and development activities. In December 2025, VYNE announced a definitive merger agreement with Yarrow Bioscience, Inc., a private biotechnology company backed by RTW Investments. Under this reverse merger, Yarrow will become a wholly owned subsidiary, and the combined company will operate under the name Yarrow Bioscience Incorporated, trading on the Nasdaq under the ticker symbol 'YARW'.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Winding down legacy BET inhibitor programs to focus resources on the clinical development of YB-101, a potential first-in-class anti-TSHR monoclonal antibody for Graves' disease and thyroid eye disease, following the merger with Yarrow Bioscience.
Expected impact: Establishes a well-funded clinical development program with a cash runway extending into 2028, targeting high unmet needs in autoimmune thyroid conditions.
Conducting a repeat non-clinical toxicology study of oral BD2-selective BET inhibitor VYN202 in male dogs to address and resolve the partial clinical hold imposed by the FDA due to testicular toxicity findings.
Expected impact: Aims to clear the FDA partial clinical hold on male subjects, enabling potential future clinical progression or out-licensing of the asset.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Combines VYNE's corporate infrastructure and remaining cash with Yarrow's promising thyroid autoimmune pipeline and a $100 million committed financing syndicate, creating a robustly funded Nasdaq-listed entity.
Terms: VYNE stockholders will receive a pre-closing cash dividend of $14.5 million to $16.5 million ($0.34 to $0.38 per share) and retain an approximate 3% ownership stake in the combined company, while Yarrow stockholders and pre-closing financing investors will own approximately 97%.
Yarrow holds exclusive global rights (excluding Greater China) to YB-101, which was in-licensed from GenSci. GenSci continues to conduct complementary clinical trials in China, including an ongoing Phase 1 trial in thyroid eye disease (TED), which will support and inform Yarrow's global clinical development strategy.
Terms: Saizeng Medical received a $70 million upfront payment, with an additional $50 million in near-term development milestones, and is eligible for up to $1.365 billion in total milestone payments plus royalties exceeding 10% of net sales.